Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma

Khiem B. Pham-Nguyen, Wen Yang, Romil Saxena, Swan N. Thung, Savio L C Woo, Shu Hsia Chen

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

IL-12 is an immuno-regulatory cytokine that has been shown to generate a potent NK and Th1 response in a variety of laboratory models. However, the detailed immune development in the hepatic tumor model by IL-12-mediated gene therapy has not been clarified. In our previous study, intratumoral transfer of Adv.mIL-12 (5 x 108 pfu) to the MCA26 colon carcinoma liver tumor induced an effective anti-tumor response, extending the median survival time from 29 to over 54 days, while 25% of the animals became tumor-free after a single treatment. In this work, we show that NK cells are responsible for the early, and both NK and T cells for the long-term, Adv.mIL-12-induced immune response. Immunohistopathological analysis of the tumor and in vitro cytotoxicity study of the mononuclear cells of the liver show that NK cells are the first to infiltrate and mediate tumor cell killing, as early as 48 hr after Adv.mIL-12 treatment. In vivo and in vitro depletion of these cells completely abolishes this early anti-tumor response. This activity can be observed in both populations of conventional NK and NKT cells in vitro and in athymic nude mice in vivo. However, the early NK response alone is not sufficient. In vivo T-cell depletion in both the primary tumor treatment and the long-term survival rechallenge study reveals that T cells in addition to NK cells are required in the development of the long-term survival and immunity attributed to Adv.mIL-12 gene therapy in this orthotopic tumor model of colon carcinoma.

Original languageEnglish (US)
Pages (from-to)813-819
Number of pages7
JournalInternational Journal of Cancer
Volume81
Issue number5
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Interleukin-12
Natural Killer Cells
Colon
Carcinoma
T-Lymphocytes
Liver
Neoplasms
Nude Mice
Genetic Therapy
Natural Killer T-Cells
Immunity
Therapeutics
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. / Pham-Nguyen, Khiem B.; Yang, Wen; Saxena, Romil; Thung, Swan N.; Woo, Savio L C; Chen, Shu Hsia.

In: International Journal of Cancer, Vol. 81, No. 5, 1999, p. 813-819.

Research output: Contribution to journalArticle

Pham-Nguyen, Khiem B. ; Yang, Wen ; Saxena, Romil ; Thung, Swan N. ; Woo, Savio L C ; Chen, Shu Hsia. / Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. In: International Journal of Cancer. 1999 ; Vol. 81, No. 5. pp. 813-819.
@article{163a8d0445964db7b29780aaf34865ce,
title = "Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma",
abstract = "IL-12 is an immuno-regulatory cytokine that has been shown to generate a potent NK and Th1 response in a variety of laboratory models. However, the detailed immune development in the hepatic tumor model by IL-12-mediated gene therapy has not been clarified. In our previous study, intratumoral transfer of Adv.mIL-12 (5 x 108 pfu) to the MCA26 colon carcinoma liver tumor induced an effective anti-tumor response, extending the median survival time from 29 to over 54 days, while 25{\%} of the animals became tumor-free after a single treatment. In this work, we show that NK cells are responsible for the early, and both NK and T cells for the long-term, Adv.mIL-12-induced immune response. Immunohistopathological analysis of the tumor and in vitro cytotoxicity study of the mononuclear cells of the liver show that NK cells are the first to infiltrate and mediate tumor cell killing, as early as 48 hr after Adv.mIL-12 treatment. In vivo and in vitro depletion of these cells completely abolishes this early anti-tumor response. This activity can be observed in both populations of conventional NK and NKT cells in vitro and in athymic nude mice in vivo. However, the early NK response alone is not sufficient. In vivo T-cell depletion in both the primary tumor treatment and the long-term survival rechallenge study reveals that T cells in addition to NK cells are required in the development of the long-term survival and immunity attributed to Adv.mIL-12 gene therapy in this orthotopic tumor model of colon carcinoma.",
author = "Pham-Nguyen, {Khiem B.} and Wen Yang and Romil Saxena and Thung, {Swan N.} and Woo, {Savio L C} and Chen, {Shu Hsia}",
year = "1999",
doi = "10.1002/(SICI)1097-0215(19990531)81:5<813::AID-IJC24>3.0.CO;2-I",
language = "English (US)",
volume = "81",
pages = "813--819",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma

AU - Pham-Nguyen, Khiem B.

AU - Yang, Wen

AU - Saxena, Romil

AU - Thung, Swan N.

AU - Woo, Savio L C

AU - Chen, Shu Hsia

PY - 1999

Y1 - 1999

N2 - IL-12 is an immuno-regulatory cytokine that has been shown to generate a potent NK and Th1 response in a variety of laboratory models. However, the detailed immune development in the hepatic tumor model by IL-12-mediated gene therapy has not been clarified. In our previous study, intratumoral transfer of Adv.mIL-12 (5 x 108 pfu) to the MCA26 colon carcinoma liver tumor induced an effective anti-tumor response, extending the median survival time from 29 to over 54 days, while 25% of the animals became tumor-free after a single treatment. In this work, we show that NK cells are responsible for the early, and both NK and T cells for the long-term, Adv.mIL-12-induced immune response. Immunohistopathological analysis of the tumor and in vitro cytotoxicity study of the mononuclear cells of the liver show that NK cells are the first to infiltrate and mediate tumor cell killing, as early as 48 hr after Adv.mIL-12 treatment. In vivo and in vitro depletion of these cells completely abolishes this early anti-tumor response. This activity can be observed in both populations of conventional NK and NKT cells in vitro and in athymic nude mice in vivo. However, the early NK response alone is not sufficient. In vivo T-cell depletion in both the primary tumor treatment and the long-term survival rechallenge study reveals that T cells in addition to NK cells are required in the development of the long-term survival and immunity attributed to Adv.mIL-12 gene therapy in this orthotopic tumor model of colon carcinoma.

AB - IL-12 is an immuno-regulatory cytokine that has been shown to generate a potent NK and Th1 response in a variety of laboratory models. However, the detailed immune development in the hepatic tumor model by IL-12-mediated gene therapy has not been clarified. In our previous study, intratumoral transfer of Adv.mIL-12 (5 x 108 pfu) to the MCA26 colon carcinoma liver tumor induced an effective anti-tumor response, extending the median survival time from 29 to over 54 days, while 25% of the animals became tumor-free after a single treatment. In this work, we show that NK cells are responsible for the early, and both NK and T cells for the long-term, Adv.mIL-12-induced immune response. Immunohistopathological analysis of the tumor and in vitro cytotoxicity study of the mononuclear cells of the liver show that NK cells are the first to infiltrate and mediate tumor cell killing, as early as 48 hr after Adv.mIL-12 treatment. In vivo and in vitro depletion of these cells completely abolishes this early anti-tumor response. This activity can be observed in both populations of conventional NK and NKT cells in vitro and in athymic nude mice in vivo. However, the early NK response alone is not sufficient. In vivo T-cell depletion in both the primary tumor treatment and the long-term survival rechallenge study reveals that T cells in addition to NK cells are required in the development of the long-term survival and immunity attributed to Adv.mIL-12 gene therapy in this orthotopic tumor model of colon carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0032962942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032962942&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19990531)81:5<813::AID-IJC24>3.0.CO;2-I

DO - 10.1002/(SICI)1097-0215(19990531)81:5<813::AID-IJC24>3.0.CO;2-I

M3 - Article

C2 - 10328238

AN - SCOPUS:0032962942

VL - 81

SP - 813

EP - 819

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -